How to Help Your Patients Find Rytary in Stock: A Provider's Guide

For many Parkinson's disease patients, Rytary (carbidopa and levodopa extended-release capsules) is a cornerstone of their motor symptom management. When patients can't reliably fill their prescription, the consequences are significant — motor deterioration, increased off time, and in cases of abrupt discontinuation, risk of neuroleptic malignant syndrome (NMS).

This guide gives clinicians a practical playbook for proactively ensuring their patients can access Rytary — from prescription workflow to pharmacy selection to patient counseling.

Why Rytary Access Is Challenging: The Provider's Perspective

Rytary is available — it is not on the FDA or ASHP shortage list. However, it presents several access barriers that providers should anticipate:

Not routinely stocked at retail pharmacies. Most chain pharmacies (CVS, Walgreens) maintain little to no Rytary inventory due to its high cost and relatively low prescription volume. Standard pharmacy fill expectations do not apply.

Multiple strengths required. Rytary comes in four strengths (23.75/95 mg, 36.25/145 mg, 48.75/195 mg, 61.25/245 mg), and most patients require combinations. A pharmacy must stock all prescribed strengths.

Prior authorization delays. Most plans require PA, which can take days and create a gap in therapy if not initiated before the first fill.

Cost-driven abandonment. At $800–$1,500/month without insurance, patients who discover the cost at the pharmacy counter often abandon the prescription. Proactive savings card enrollment prevents this.

Step 1: Establish a Relationship with a Specialty Pharmacy

The single most impactful change most movement disorder practices can make is routing all Rytary prescriptions through a designated specialty pharmacy rather than leaving patients to navigate retail chains on their own. Specialty pharmacies that serve neurological patients maintain Rytary inventory and often have navigator services to handle prior authorizations.

When establishing a specialty pharmacy relationship, confirm: (1) all four Rytary strengths are available, (2) they can handle your patient population's insurance mix, and (3) they have clinical pharmacist support for PA submissions.

Step 2: Initiate Prior Authorization Before the First Fill

Prior authorization for Rytary should be submitted at the time of prescribing — not when the patient is standing at the pharmacy counter. Build a PA initiation step into your practice workflow for all new Rytary prescriptions.

In your PA submission, document:

Diagnosed Parkinson's disease (ICD-10: G20)

Current motor fluctuations: wearing off periods, dyskinesia, UPDRS scores

Prior carbidopa-levodopa IR trial with suboptimal results (step therapy requirement)

Clinical rationale for extended-release formulation (reduced off time, improved motor stability)

Step 3: Enroll Patients in the Amneal Savings Program at Prescribing

Amneal Pharmaceuticals (Rytary's manufacturer) partners with PhilRx to offer a copay savings program for commercially insured patients. This can reduce monthly copays to $0–$20. Have your medical assistant provide savings card enrollment information to every commercially insured Rytary patient at the time of prescribing. This step eliminates cost-driven prescription abandonment for the majority of commercially insured patients.

Note: This program is not available for Medicare, Medicaid, or government-funded patients. For these patients, explore patient assistance programs through Amneal or refer to a patient advocacy organization.

Step 4: Use medfinder for Providers to Check Availability

Before writing a Rytary prescription for a new patient, you can use medfinder for Providers to check real-time pharmacy availability in the patient's zip code. This allows you to direct the prescription to a pharmacy that is already stocked — reducing the delay between prescription writing and first fill.

Step 5: Counsel Patients on Refill Timing and Safety

All Rytary patients should receive explicit counseling on these points:

Begin refill process 7–10 days before supply runs out

Never abruptly stop Rytary — risk of NMS with sudden withdrawal

Do not chew, crush, or divide capsules — can sprinkle on applesauce for dysphagia

High-fat, high-calorie meals can delay levodopa absorption by ~2 hours — take first dose before breakfast

Contact your office immediately if they can't find Rytary — do not attempt to self-substitute with another formulation

When to Consider Switching Away from Rytary

If a patient experiences recurrent access problems despite all the above strategies, it may be worth reassessing whether Crexont (approximately 1:1 levodopa conversion, twice-daily dosing) would provide equivalent symptom control with fewer logistical barriers. Crexont was approved in 2024 and is similarly available through specialty pharmacy channels. For patients with severe motor fluctuations despite ER therapy, Duopa (enteral suspension) remains an option in appropriate candidates. For a comparison of all options, refer patients to our guide on alternatives to Rytary.